Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Crossref DOI link: https://doi.org/10.1007/s00520-015-3036-7
Published Online: 2015-11-25
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Weycker, Derek
Li, Xiaoyan
Figueredo, Jacqueline
Barron, Rich
Tzivelekis, Spiros
Hagiwara, May
Funding for this research was provided by:
Amgen (US)
License valid from 2015-11-25